CMS's current inclusion of noncovered self-administered drug prices in Medicare Part B payment calculations inflates costs for Stelara biosimilars. OIG recommends revising pricing methodology to achieve savings.

House Republicans release a health care cost plan focusing on association health plans and drug pricing transparency, excluding an extension of ACA subsidies amid party divisions.

Study shows biosimilar bevacizumab reduces Medicare costs for metastatic colorectal and lung cancer treatments, expanding patient access without raising spending.

Key health policy trends for 2026 include ACA premium challenges, Medicaid work requirements, rising health costs, drug pricing pressure, and advancing healthcare AI impacting U.S. insurance markets.

Medicaid cuts and the expiration of ACA subsidies under the OBBBA are causing premium increases and coverage challenges in the U.S. health insurance market, with legislative and regulatory efforts underway.

The expiration of enhanced ACA subsidies in 2025 highlights opportunities for reforms in Health Savings Accounts, Association Health Plans, and Pharmacy Benefit Manager incentives to improve healthcare transparency and affordability.

Eli Lilly cuts prices for cash buyers of Zepbound, impacting pharmaceutical pricing and payer coverage dynamics.

Explore how over 30 U.S. states have enacted drug price transparency laws requiring manufacturers, health plans, and PBMs to report pricing data, aiding state efforts to analyze and regulate high prescription drug costs.

Explore critical 2025 U.S. healthcare developments affecting insurance markets, from vaccine safety and measles resurgence to drug pricing reforms and medical education loan caps.

Medicare's Inflation Reduction Act negotiations cut prices for 15 top prescription drugs by 44%, reducing out-of-pocket costs and impacting Medicare Part D and Part B markets.